Citadel Advisors’s Genelux GNLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-19,415
Closed -$84.6K 13449
2025
Q4
$84.6K Sell
19,415
-14,828
-43% -$80.1K ﹤0.01% 11758
2025
Q3
$144K Buy
+34,243
New +$122K ﹤0.01% 11559
2025
Q2
Sell
-57,890
Closed -$156K 13465
2025
Q1
$156K Buy
57,890
+38,436
+198% +$144K ﹤0.01% 10813
2024
Q4
$45.9K Sell
19,454
-39,112
-67% -$104K ﹤0.01% 12476
2024
Q3
$139K Buy
58,566
+43,655
+293% +$96.1K ﹤0.01% 10667
2024
Q2
$29.1K Sell
14,911
-29,849
-67% -$101K ﹤0.01% 12304
2024
Q1
$288K Buy
+44,760
New +$407K ﹤0.01% 9536
2023
Q2
Sell
-10,615
Closed -$294K 14665
2023
Q1
$294K Buy
+10,615
New +$172K ﹤0.01% 9411

Other funds holding GNLX

Citadel Advisors's GNLX Position: Q1 2026 in Review

Citadel Advisors sold out of Genelux (GNLX) in Q1 2026, closing a stake of 19,415 shares — an estimated $84.6K sold.

Citadel Advisors first reported a position in GNLX in Q1 2023 and held it in 8 quarters. The position peaked at $294K in Q1 2023. 71 funds tracked by Wall St. Rank hold GNLX as of Q1 2026.

  • Citadel Advisors reported no remaining Genelux position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 19,415 Genelux shares in Q1 2026, an estimated $84.6K.
  • Citadel Advisors first reported a position in Genelux in Q1 2023 and held it in 8 quarters.
  • Citadel Advisors's Genelux position peaked at $294K in Q1 2023.
  • 71 funds tracked by Wall St. Rank held Genelux as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.